Navigation Links
AstraZeneca Initiates Phase 3 Clinical Trial For Selumetinib In Non-Small Cell Lung Cancer
Date:10/22/2013

BOULDER, Colo., Oct. 22, 2013 /PRNewswire/ -- AstraZeneca today announced the first patient randomized in a Phase 3 clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer (NSCLC) whose tumors are KRAS mutation-positive.  

(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)

Array BioPharma (NASDAQ:   ARRY) invented and licensed worldwide rights to develop and commercialize selumetinib to AstraZeneca in 2003.  The initiation of the Phase 3 trial triggered a $5 million milestone payment to Array.  Array retains significant economic rights to selumetinib under the agreement with AstraZeneca, including double digit royalties on global commercial sales and the potential for approximately $70 million in additional milestone payments. 

Ron Squarer, Chief Executive Officer, Array BioPharma noted, "The initiation of the Phase 3 SELECT-1 trial highlights AstraZeneca's on-going commitment to develop selumetinib broadly in areas of high unmet need.  Together with the active pivotal trial in thyroid cancer and the announced uveal melanoma trial, there are already three paths to market for selumetinib."

The SELumetinib Evaluation as Combination Therapy-1 (SELECT-1) study is a randomized, double-blind, placebo-controlled study that will evaluate the safety and efficacy of selumetinib plus docetaxel as a second line therapy in locally advanced or metastatic KRAS mutation-positive NSCLC.  The study is designed to evaluate Progression Free Survival (PFS) as the primary endpoint and Overall Survival (OS) as a secondary endpoint. AstraZeneca has reported that SELECT-1 will include 220 centers globally and enroll 634 patients, who will be randomized in a rati
'/>"/>

SOURCE Array BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
2. Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
3. Omthera Stockholders Approve Acquisition by AstraZeneca
4. AstraZeneca Neuroscience partners with ePharmaSolutions to optimize Clinical Trial Management
5. Isis Pharmaceuticals Earns $6 Million Payment from AstraZeneca
6. Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca
7. AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
8. AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation
9. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
10. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
11. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Nonin Medical, a global leader in noninvasive ... Officer Steve Bucholz will retire May 1. ... role as Chief Executive Officer. In addition, Mr. Isaacson ... Operations will transition to David Noel , Chief ... been instrumental to Nonin Medical,s growth," Mr. Isaacson said. ...
(Date:4/17/2015)... , Apr. 17, 2015 Research and Markets ... addition of the "Medical Device Outsourcing - ... offering. This report analyzes the worldwide ... by the following Device Categories: Class I, Class ... analyzed in the report Include - Radiology, Orthopedic, ...
(Date:4/17/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lmsnqn/medical_equipment ) has ... and Leasing - Global Strategic Business Report" report ... worldwide markets for Medical Equipment Rental and Leasing in ... the US, Japan , ... Annual estimates and forecasts are provided for the period ...
Breaking Medicine Technology:Nonin Medical's Philip Isaacson Expands CEO Role; President and COO Steve Bucholz to Retire May 1 2Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 2Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 3Medical Equipment Rental and Leasing Market 2015-2020 - Global Strategic Business Report - Healthcare Spending Slowdown Bodes Well for Medical Equipment Leasing 2
(Date:4/17/2015)... DC (PRWEB) April 17, 2015 Representatives ... HHT Diagnoses and Treatment Act HR 1849 in congress ... diagnosis rates and treatment for patients with the genetic ... in the past, would be the first to create ... and appropriate treatment of hereditary hemorrhagic telangiectasia. This would ...
(Date:4/17/2015)... York (PRWEB) April 17, 2015 ... allege this class of prescription medications increases the ... attack, stroke or other life-threatening cardiovascular event continue ... U.S. District Court, Northern District of Illinois. According ... U.S. Judicial Panel on Multidistrict Litigation (JPML) on ...
(Date:4/17/2015)... Connie Casad, M.D., a well-known and ... with 30 years of practice experience in Dallas, Texas, ... of service for her patients with the availability of ... wellness books with a brief synopsis on each for ... interest in providing this service, Dr. Casad said, “Furnishing ...
(Date:4/17/2015)... released a new blog post explaining the dangers of sleeping ... rates . , Falling asleep at the wheel can ... impact on auto insurance prices. The premiums will go up ... newly released blog post talks more about drowsiness at the ... is now possible to find low cost car insurance plans ...
(Date:4/17/2015)... According to the Asthma and Allergy ... suffer from all types of allergies, including indoor/outdoor, food ... to comprehensive allergy testing that’s being offered by CareMed ... a way to get recommended treatment to enjoy the ... allergens, can vary by region of the country and ...
Breaking Medicine News(10 mins):Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 2Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 3Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 4Health News:Connie Casad, M.D. Provides Patients Recommended List of Wellness Books on Website 2Health News:Accidents Caused By Sleeping at The Wheel Can Increase Auto Insurance Costs 2Health News:CareMed Urgent & Primary Care Now Offering Comprehensive Allergy Testing 2Health News:CareMed Urgent & Primary Care Now Offering Comprehensive Allergy Testing 3
... Mich. A gene well known to stop or suppress cancer ... study from the University of Michigan Comprehensive Cancer Center. The researchers ... affected the growth of breast cancer stem cells. Further, by ... an up to 90 percent decrease in the number of cancer ...
... As the summer ... Diet developed at the U.S. Department of Energy,s Argonne National Laboratory. , ... Argonne, Ill. (Vocus) June 1, 2009 -- As ... the Anti-Jet-Lag Diet developed at the U.S. Department of Energy,s Argonne National Laboratory. , , ...
... the most clinically complex children , , STREAMWOOD, Ill., ... its new 30,000-square-foot Children,s Center addition has opened and begun ... bed count from 120 to 162 and better serve the ... to the community and our partners for supporting us in ...
... in peer-reviewed journals have shown the benefits of AHCC against ... , BEAVERTON, Ore., June 1 A study evaluating the ... immune system in response to the swine flu virus will ... the few research centers in China that have been approved ...
... BetterU Transforms Total Health Through Free Online Makeover , ... the No. 1 killer of women in the U.S. That,s why ... across the country to listen to their hearts and turn their ... BetterU! Go Red BetterU is not about fad diets and new ...
... , , YONKERS, N.Y., June 1 ... that consumers pay high prices and get mediocre fittings. The new report ... a comprehensive guide to purchasing and owning a hearing aid. ... of Consumer Reports and online at www.consumerreportsenespanol.org ...
Cached Medicine News:Health News:U-M researchers link pathway to breast cancer stem cells 2Health News:Argonne Anti-Jet-Lag Diet Helps Summer Travelers Beat Jet Lag 2Health News:Streamwood Hospital Opens New Children's Center to Meet Vital Community Need 2Health News:Study to Investigate AHCC and the Swine Flu Virus 2Health News:Go Red For Women(R) Launches 12-Week Program to Improve Heart Health and Save Lives 2Health News:Go Red For Women(R) Launches 12-Week Program to Improve Heart Health and Save Lives 3Health News:Consumer Reports: Hearing Aid Shoppers Pay High Prices, Get Mediocre Fittings 2Health News:Consumer Reports: Hearing Aid Shoppers Pay High Prices, Get Mediocre Fittings 3Health News:Consumer Reports: Hearing Aid Shoppers Pay High Prices, Get Mediocre Fittings 4
The Salt A-Peel™ microdermabrasion combines, positive air pressure, pure salt, ultrasound and the application of rich anti oxidant products to deliver a remarkable 'The Salt A-Peel' anti ageing...
... introduces the DiamondTome™ Skin Resurfacing System ... DiamondTome™ Wands, an evolution in microdermabrasion ... smoother, more youthful skin. , For ... benefits of DiamondTome's™ innovative approach to ...
... your aesthetic practice with the advantages of ... that's gentle, powerful and fast. With ever-increasing ... of IPL Skin Treatments using Photorejuvenation, the ... an indispensable tool for all aesthetic physicians, ...
Disposable. Sterile Suction Tubing....
Medicine Products: